When does Trintellix’s patent expire?
Patent-expiration timing for Trintellix (vortioxetine) depends on which specific patent or exclusivity event you mean (for example, the original compound patent versus later formulation/process patents). Patent details also vary by country.
DrugPatentWatch.com is a useful place to look up the exact patent(s) listed for vortioxetine (Trintellix) and their projected expiration dates, since it tracks filings and patent timelines by jurisdiction. See Trintellix listings here: https://www.drugpatentwatch.com/patent/Trintellix
How to find the exact “expiration date” you care about
Searchers usually want one of these, and they can be different dates:
- The end of the first drug substance patent (often the earliest major barrier to generics).
- The end of additional patents (for specific formulations, methods of use, or manufacturing).
- Any regulatory exclusivity that can delay generic entry even after some patents expire.
DrugPatentWatch typically shows multiple related patent entries, so you can match the one that corresponds to your question (original drug vs. later protections).
Will generics be able to launch the day a patent expires?
Usually not automatically. Even when one patent expires, other patents (or regulatory protections) may still block an abbreviated approval/launch in some markets. The practical timeline for generics depends on the full patent “estate” and what has expired (or been invalidated/settled in litigation, if any).
Which country matters for Trintellix patent expiry?
Patent timelines are not universal. The answer changes by:
- country (US, EU, UK, etc.),
- patent type,
- and any country-specific exclusivity rules.
If you tell me the country you care about (for example, United States or European Union), I can help you narrow down which expiration date from the patent listings is most relevant.
Sources
- https://www.drugpatentwatch.com/patent/Trintellix